ArQule, Inc. is engaged in the research, development, and commercialization of broadly effective, small molecule cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. ArQule's lead clinical-stage products are based on its Activated Checkpoint TherapySM platform, designed to restore and activate cellular checkpoints, and on its Cancer Survival Pathway platform, designed to block the c-Met receptor tyrosine kinase. Pre-clinical programs are focused on multiple additional biological targets implicated in the growth of cancer. The targets, mechanisms of action and chemistry related to compounds generated from ArQule’s oncology programs differ, offering the potential for multiple therapeutic opportunities. Throughout these programs, the Company's molecular biology capabilities are enhanced by its strengths in chemistry technology.